Since IL‐1β is a pro‐inflammatory cytokine which may contribute to the pathogenesis of inflammatory bowel disease (IBD) [28, 29, 30], while IL‐6 and IL‐10 are associated with colon epithelial cell proliferation [31, 32], we investigated the influence of CRAMP deficiency in myeloid or epithelial cells on the plasma levels of IL‐1β, IL‐6, and IL‐10 after DSS treatment. Here, IL1B is linked to inflammatory bowel disease.